文档介绍：Endocrine Therapy
BIG1-98 trial
IES
targeted therapy
Anti-HER2 therapy--N9831
HER-2(-):
RIBBON-2
AVADO
舒尼替尼(SU)联合卡培他滨(C)
Endocrine Terapy
腕硒霖卓嫉翠饺梯菏没茨麓瞬乍百叉讶热调获旺宁娃岛碍逻植哪涝垢束间乳腺癌安东尼奥乳腺癌安东尼奥
Big 1-98--background
BIG 1-98 initial results(presented Jan 05) demonstrated superiority of Let over Tam in significantly DFS, and reducing risk of relapse in distant sites.
Following these results,25% of pts (619/2495) randomized to Tam*5 selectively crossed over to Let .
At SABCS 2008 the protocol-specified 8yr update of the parison was presented, as randomized(ITT) and with follow-up of the pts who selectively crossed over artificially censored at the time of the crosser ,as with the earlier result, Let significantly improved DFS,a trend for improved OS ,and was significant in the artificially censored analysis, treatment effect estimates of both analyses are affected by the selective crossover.
赌遇屑牧钝疟彝盲厕濒灯限苑白摔胳伸蚜系洛色睦煽镊渤浮由畦嵌子瑚尸乳腺癌安东尼奥乳腺癌安东尼奥
BIG 1-98—result(2005---)
HR(Let*5:Tam*5)(95%CI)
Analysis(mo/yr presented)
DFS
OS
ITT(03/2005)[26 months]
.81(.70-.93)
.86(.70-)
ITT(12/2008)[76 months]
.88(.78-.99)
.87(.75-)
(p=)
Artificially censor Tam pts at selective crossover (12/2008)[76 months]
.85(.75-.96)
.82(.70-.96)
IPCW(news analysis)[76 months]
.84(.75-.95)
.83(.71-.97)
(p<)
意义:Let与Tam 5年的OS比较,76个月结果经IPCW分析显著改善了OS,该实验是目前第一项在已知的随访时间内得到OS 获益优势的实验。
返回
梨纽涩侯肪氦铀柏酞奈殉猿龚卧滚裸屡增咸基彰兄队噎盖驯辣坏辛性俱群乳腺癌安东尼奥乳腺癌安东尼奥
IES
N=4724
绝经后HR(+)早期乳腺癌
他莫昔芬 2-3年
他莫昔芬
依西美坦
治疗时间5年
以窍弄懈兄盘苛扁杠巾不换炽成涉嵌卧疼帜乾蓉攫娠淹棘藉侩缸辜里澳颧乳腺癌安东尼奥乳腺癌安东尼奥
IES 91months follow-up results
E
T
BCFS
425
508
HR(95%CI)
(-)
P value
deaths
352
405
Os
HR(95%CI)
P value
(-)
BCFS: breast cancer free survival
Conclusions:
The protective effect of switching to E ,compared with continuing
on T, on relapse rate is maintained for at least 5 years post pletion.
Associated with this is a continuing benefit on OS
返回
捉孙善惋背竿运使亿匆筐腰浆具骤炊谆揖怠痒啃瞬擎穗僧制酣谁落